SCHEMBL6718964

SCHEMBL6718964

Cc1onc(-c2ccc(C(F)(F)F)cc2)c1-c1ccc(S(C)(=O)=O)c(F)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 9/20 0.53
POLB P06746 1/20 0.43
NPSR1 Q6W5P4 2/20 0.43
PAX8 Q06710 1/20 0.43
KDM4E B2RXH2 1/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
MCOLN3 Q8TDD5 1/20 0.43
MT-CO2 P00403 3/20 0.42
PTGS1 P23219 2/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
LMNA P02545 1/20 0.42
CA3 P07451 1/20 0.42
ADRB2 P07550 1/20 0.42
ADRB1 P08588 1/20 0.42
CYP3A4 P08684 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
CHRM1 P11229 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6723038 0.90 PTGS2 (0.54) PTGS2NPSR1PAX8KDM4EGAA
SCHEMBL6722905 0.89 PTGS2 (0.46) PTGS2NPSR1PAX8KDM4EGAA
SCHEMBL6722083 0.88 PTGS2 (0.59) PTGS2POLBALOX5APFEN1MEN1
SCHEMBL6723394 0.88 PTGS2 (0.68) PTGS2PAX8MT-CO2PTGS1CA12
SCHEMBL6730227 0.88 PTGS2 (0.57) PTGS2NPSR1PAX8GAAMAPT
SCHEMBL6728418 0.87 PTGS2 (0.49) PTGS2POLBNPSR1PAX8KDM4E
SCHEMBL6735956 0.87 PTGS2 (0.54) PTGS2POLBNPSR1PAX8KDM4E
SCHEMBL14267629 0.87 PTGS2 (0.56) PTGS2NPSR1PAX8GAAMAPT
SCHEMBL6723761 0.87 PTGS2 (0.56) PTGS2NPSR1PAX8GAAMAPT
SCHEMBL6516199 0.87 PTGS2 (0.56) PTGS2PAX8MT-CO2PTGS1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-05-13 US disclosed
EP-1296971-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2003-04-02 EP disclosed
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2002-12-05 US disclosed
WO-2001081332-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, FPR1, PTGES2 PTGS2 5/4885POLB 3233/4885NPSR1 641/4885
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, PTGES2, FPR1 PTGS2 5/4885POLB 3122/4885NPSR1 618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.